Pieris Pharmaceuticals Inc (PIRS)
12.00
+0.31
(+2.67%)
USD |
NASDAQ |
Apr 23, 16:00
11.86
-0.14
(-1.17%)
After-Hours: 20:00
Pieris Pharmaceuticals Enterprise Value: -11.53M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | -11.53M |
| April 22, 2024 | -11.91M |
| April 19, 2024 | -12.02M |
| April 18, 2024 | -11.01M |
| April 17, 2024 | -10.82M |
| April 16, 2024 | -10.14M |
| April 15, 2024 | -9.547M |
| April 12, 2024 | -9.376M |
| April 11, 2024 | -8.914M |
| April 10, 2024 | -8.825M |
| April 09, 2024 | -8.379M |
| April 08, 2024 | -9.240M |
| April 05, 2024 | -9.369M |
| April 04, 2024 | -9.398M |
| April 03, 2024 | -9.132M |
| April 02, 2024 | -8.755M |
| April 01, 2024 | -7.865M |
| March 28, 2024 | -8.241M |
| March 27, 2024 | -7.202M |
| March 26, 2024 | -7.766M |
| March 25, 2024 | -8.389M |
| March 22, 2024 | -6.579M |
| March 21, 2024 | -6.589M |
| March 20, 2024 | -5.589M |
| March 19, 2024 | -5.045M |
| Date | Value |
|---|---|
| March 18, 2024 | -5.589M |
| March 15, 2024 | -9.646M |
| March 14, 2024 | -9.448M |
| March 13, 2024 | -9.122M |
| March 12, 2024 | -9.448M |
| March 11, 2024 | -9.547M |
| March 08, 2024 | -8.558M |
| March 07, 2024 | -8.765M |
| March 06, 2024 | -9.636M |
| March 05, 2024 | -9.349M |
| March 04, 2024 | -9.557M |
| March 01, 2024 | -9.250M |
| February 29, 2024 | -10.03M |
| February 28, 2024 | -9.537M |
| February 27, 2024 | -10.48M |
| February 26, 2024 | -9.943M |
| February 23, 2024 | -10.28M |
| February 22, 2024 | -10.41M |
| February 21, 2024 | -9.537M |
| February 20, 2024 | -9.636M |
| February 16, 2024 | -10.91M |
| February 15, 2024 | -10.66M |
| February 14, 2024 | -11.03M |
| February 13, 2024 | -10.99M |
| February 12, 2024 | -10.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-38.52M
Minimum
Jun 30 2023
271.17M
Maximum
Sep 17 2021
65.97M
Average
67.91M
Median
Nov 09 2020
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.275M |
| Palatin Technologies Inc | 18.75M |
| iBio Inc | 16.49M |
| Theriva Biologics Inc | -13.75M |
| Oragenics Inc | 3.306M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.584M |
| Revenue (Quarterly) | 1.299M |
| Total Expenses (Quarterly) | 6.781M |
| EPS Diluted (Quarterly) | -3.20 |
| Profit Margin (Quarterly) | -352.9% |
| Earnings Yield | -186.7% |
| Normalized Earnings Yield | -92.83 |